Flourish Research/Merritt Island Medical Research
Welcome,         Profile    Billing    Logout  
 1 Trial 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rice, Taylor
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
Feinberg, Marc
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
ADAPT oculus, NCT06558279: A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

Recruiting
3
124
Europe, Canada, Japan, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Myasthenia Gravis, Ocular
12/25
12/27
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
10/24
10/24
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Recruiting
2
30
Canada, US
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
03/25
03/26
SYNAPSE-MG, NCT06414954: Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Recruiting
2
84
Europe, US, RoW
NMD670, Placebo
NMD Pharma A/S
Myasthenia Gravis, Myasthenia Gravis, MuSK
11/25
11/25
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
NCT06298565: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Recruiting
N/A
680
Europe, US
efgartigimod
argenx
Myasthenia Gravis
06/34
06/34
Schirtzer, Emily
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
Andreen, Alyssa
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences, National Institute on Aging (NIA)
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
09/25
10/25
Coerver, Katherine
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rice, Taylor
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
Feinberg, Marc
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
ADAPT oculus, NCT06558279: A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

Recruiting
3
124
Europe, Canada, Japan, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Myasthenia Gravis, Ocular
12/25
12/27
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
10/24
10/24
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Recruiting
2
30
Canada, US
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
03/25
03/26
SYNAPSE-MG, NCT06414954: Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Recruiting
2
84
Europe, US, RoW
NMD670, Placebo
NMD Pharma A/S
Myasthenia Gravis, Myasthenia Gravis, MuSK
11/25
11/25
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
NCT06298565: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Recruiting
N/A
680
Europe, US
efgartigimod
argenx
Myasthenia Gravis
06/34
06/34
Schirtzer, Emily
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
Andreen, Alyssa
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences, National Institute on Aging (NIA)
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
09/25
10/25
Coerver, Katherine
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28

Download Options